98224-27-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzo[1,3]dioxol-4-yl-piperazin is used as a pharmaceutical compound for its potential therapeutic applications. The presence of the benzo[1,3]dioxol moiety in its structure may contribute to its bioactivity, making it a candidate for the development of drugs targeting various medical conditions.
1. As a potential treatment for psychiatric disorders:
1-Benzo[1,3]dioxol-4-yl-piperazin is used as a therapeutic agent for psychiatric disorders due to its potential pharmacological activity. Piperazine derivatives have been studied for their use in treating such conditions, and the presence of the benzo[1,3]dioxol group in 1-BENZO[1,3]DIOXOL-4-YL-PIPERAZINE may enhance its efficacy in modulating neurotransmitter systems involved in psychiatric disorders.
2. As a potential treatment for neurological diseases:
1-Benzo[1,3]dioxol-4-yl-piperazin is used as a therapeutic agent for neurological diseases, leveraging its potential bioactive properties. The benzo[1,3]dioxol moiety may contribute to its ability to target specific receptors or pathways involved in neurological conditions, offering a new avenue for drug development in this field.
3. As a subject of interest in pharmaceutical research and development:
1-Benzo[1,3]dioxol-4-yl-piperazin is used as a research compound to explore its potential pharmacological activity and applications in drug development. Its unique structure, including the benzo[1,3]dioxol group, makes it a promising candidate for further investigation into its therapeutic potential and possible use in treating various medical conditions.

InChI:InChI=1/C11H14N2O2/c1-2-9(13-6-4-12-5-7-13)11-10(3-1)14-8-15-11/h1-3,12H,4-8H2

Upstream product

• 1668-84-4 benzo[d][1,3]dioxol-4-amine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 72744-45-7 4-nitro-(1,3-benzodioxolyl) 
• 6665-98-1 3-nitrobenzene-1,2-diol 

Relevant academic research and scientific papers

Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT1A receptors

It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]-thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (Ki 1A receptors (Ki 35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h-j and 8j,1 antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.